Posts

Smart Cancer Resources & Research Guide 2026: A Patient-First Map of Diagnosis, Biomarkers, Treatment, Immunotherapy, Resistance & Integrative Oncology

Image
OneDayMD Cancer Resource Library · Network Index · Published September 17, 2026 · Last reviewed and updated November 2026 (v2.1) Cancer information is no longer confined to a single textbook, treatment guideline, or hospital website — and cancer guides should not be limited to oncologists. Modern oncology now spans pathology, staging, molecular biomarkers, precision medicine, prevention, surgery, radiation, chemotherapy, targeted therapy, immunotherapy, cellular therapy, cancer metabolism, treatment resistance, supportive care, and clinical research. This OneDayMD guide brings those subjects together in one navigable resource. Rather than hundreds of disconnected articles, it offers a pathway through the evidence and links directly to deeper OneDayMD, SmartCancer, and Cancer Advisor resources. Quick Answer This page is a map, not a single treatment guide — it connects the OneDayMD network's cancer content by the question you're actually asking. Newly diagnosed and ...

DARA-IM: An Integrated In Silico Phase Ib/II Clinical Trial of Daraxonrasib Plus Ivermectin and Mebendazole Versus Daraxonrasib Monotherapy in Previously Treated Stage IV Pancreatic Cancer

Image
Article type: Proposed research protocol and computational modelling framework Research group: OneDayMD / SmartCancer Research Team Protocol version: 1.2 Protocol date: 17 November 2026 Study designation: DARA-IM (Daraxonrasib–Ivermectin–Mebendazole) Clinical setting: Second-line treatment of metastatic pancreatic ductal adenocarcinoma (PDAC) Research design: Integrated Phase Ib/II virtual clinical trial Research disclaimer: DARA-IM is a proposed computational and translational research protocol. The three-drug combination has not demonstrated clinical efficacy or established safety in pancreatic cancer. This article does not recommend ivermectin or mebendazole as cancer treatments, and no experimental dosing regimen is proposed for patient use. Any human investigation would require pharmacological validation, regulatory authorization and independent ethics approval. Abstract Background Metastatic pancreatic ductal adenocarcinoma (PDAC) remains a major therapeutic...

Prostate Cancer in 2026: Risk-Adapted Treatment, Diet, Supplements and Repurposed-Drug Evidence (Integrated Guide)

Medically reviewed by Dr. Frank Yap, MD | Written by OneDayMD Editorial Team | Last updated November 2026 Quick Answer Not every prostate cancer needs immediate treatment, but every prostate cancer needs a plan. In the ProtecT trial (1,643 men, 15-year follow-up), prostate-cancer death was low with active monitoring (3.1%), prostatectomy (2.2%) and radiotherapy (2.9%) with no significant difference, yet radical treatment roughly halved metastases (9.4% vs 4.7 to 5.0%) [1]. Match the intensity of treatment to biological risk: surveillance plus lifestyle for low-risk disease, individualized decisions for intermediate risk, and definitive standard therapy for high-risk, recurrent and metastatic disease. Exercise, weight control and a plant-forward, lower-glycemic diet are sensible foundations. No supplement, ketogenic diet or repurposed antipar...

Archive

Show more